Schurgers L J, Spronk H M H, Skepper J N, Hackeng T M, Shanahan C M, Vermeer C, Weissberg P L, Proudfoot D
Cardiovascular Research Institute Maastricht and VitaK, University of Maastricht, Universiteitssingel 50, Maastricht, The Netherlands.
J Thromb Haemost. 2007 Dec;5(12):2503-11. doi: 10.1111/j.1538-7836.2007.02758.x. Epub 2007 Sep 10.
Matrix Gla protein (MGP) is a small vitamin K-dependent protein containing five gamma-carboxyglutamic acid (Gla) residues that are believed to be important in binding Ca(2+), calcium crystals and bone morphogenetic protein. In addition, MGP contains phosphorylated serine residues that may further regulate its activity. In vivo, MGP has been shown to be a potent inhibitor of vascular calcification; however, the precise molecular mechanism underlying the function of MGP is not yet fully understood.
We investigated the effects of MGP in human vascular smooth muscle cell (VSMC) monolayers that undergo calcification after exposure to an increase in Ca(2+) concentration. Increased calcium salt deposition was found in cells treated with the vitamin K antagonist warfarin as compared to controls, whereas cells treated with vitamin K(1) showed decreased calcification as compared to controls. With conformation-specific antibodies, it was confirmed that warfarin treatment of VSMCs resulted in uncarboxylated (Gla-deficient) MGP. To specifically test the effects of MGP on VSMC calcification, we used full-length synthetic MGP and MGP-derived peptides representing various domains in MGP. Full length MGP, the gamma-carboxylated motif (Gla) (amino acids 35-54) and the phosphorylated serine motif (amino acids 3-15) inhibited calcification. Furthermore, we showed that the peptides were not taken up by VSMCs but bound to the cell surface and to vesicle-like structures.
These data demonstrate that both gamma-glutamyl carboxylation and serine phosphorylation of MGP contribute to its function as a calcification inhibitor and that MGP may inhibit calcification via binding to VSMC-derived vesicles.
基质γ-羧基谷氨酸蛋白(MGP)是一种维生素K依赖的小分子蛋白,含有五个γ-羧基谷氨酸(Gla)残基,据信这些残基在结合Ca(2+)、钙晶体和骨形态发生蛋白方面很重要。此外,MGP含有磷酸化的丝氨酸残基,可能进一步调节其活性。在体内,MGP已被证明是血管钙化的有效抑制剂;然而,MGP功能的确切分子机制尚未完全了解。
我们研究了MGP对人血管平滑肌细胞(VSMC)单层的影响,这些细胞在暴露于Ca(2+)浓度升高后会发生钙化。与对照组相比,用维生素K拮抗剂华法林处理的细胞中钙盐沉积增加,而用维生素K(1)处理的细胞与对照组相比钙化减少。使用构象特异性抗体证实,华法林处理VSMC会导致未羧化(缺乏Gla)的MGP。为了特异性测试MGP对VSMC钙化的影响,我们使用了全长合成MGP和代表MGP中各个结构域的MGP衍生肽。全长MGP、γ-羧化基序(Gla)(氨基酸35-54)和磷酸化丝氨酸基序(氨基酸3-15)均抑制钙化。此外,我们表明这些肽未被VSMC摄取,而是与细胞表面和囊泡样结构结合。
这些数据表明,MGP的γ-谷氨酰羧化和丝氨酸磷酸化均有助于其作为钙化抑制剂的功能,并且MGP可能通过与VSMC衍生的囊泡结合来抑制钙化。